オーファンドラッグの世界市場 – BCC Research

Global Markets for Orphan Drugs

オーファンドラッグの世界市場

Report Highlights

The global market for orphan drugs is expected to increase from $233.9 billion in 2023 to $415.2 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.2% during the forecast period of 2023-2028.

Report Scope:

The scope of this study includes orphan drugs used in the global pharmaceutical markets. This report analyzes the therapeutic applications of orphan drugs in rare and orphan diseases as well as examines the regulatory framework, patents, and recent innovations in the industry. The report also analyzes each submarket and its applications, projections, and market shares. Technological issues include the latest trends and developments.

This report covers the regional segmentation included as North America, Europe, Asia-Pacific, and Rest of the World. This report also analyzes the regulatory framework for the clinical trials of orphan drugs in rare and orphan diseases. The report examines the trends and characteristics of clinical trials conducted on rare diseases from 1999-2018, using information from various sources. In addition, this report provides an overview of the global orphan drugs market and its competitive landscape. This report also examines acquisition strategies and collaborations, discusses the market’s strengths and weaknesses considering new technologies, and analyzes the industry’s growing competition and changing customer needs.

オーファンドラッグの世界市場 - BCC Research

Report Synopsis

Report MetricsDetails
Base year considered2022
Forecast period considered2023-2028
Base year market size$210.0 billion
Market size forecast$415.2 billion
Growth rateCAGR of 12.2% for the forecast period of 2023-2028
Units considered$ Millions
Segments coveredProduct Type, Therapeutic Application, Region
Regions coveredNorth America, Europe, Asia-Pacific, Rest of the World (RoW)
Countries coveredU.S., Canada, Mexico, Spain, Italy, Netherlands, Turkey, Austria, Poland, Germany, UK, France, China, India, Japan, Australia, South Korea, Thailand, Singapore, Vietnam, Middle East and Africa
Key Market DriversFavorable Orphan Drug Act and Similar Legislation
Technological Advances in Genomics
Lack of Competition from Generic Drugs
Patent Extensions
Premium Pricing of Orphan Drugs
Innovations in Manufacturing Technologies
Increasing Collaborations and Licensing Agreements
Companies studiedABBVIE INC.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BRISTOL MYERS SQUIBB
EISAI CO. LTD.
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI S.A.
TAKEDA PHARMACEUTICAL CO. LTD.